This drug not only reduced the inflammatory responses in adipocytes (e.g., it caused a downregulation of inflammatory markers such as tumor necrosis factor-α and interleukin-6) but also in vivo Bay-X-1005 prevented hepatic steatosis created in a mouse model of dietary obesity [14]. The gene discussed is IL6; the disease is fatty liver disease.